Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 10/20 | 0.48 |
| ▸ | PDE4A | P27815 | 6/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3697869 | 0.93 | PDE4A (0.52) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7849110 | 0.93 | TNF (0.43) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7847357 | 0.92 | TNF (0.46) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3693500 | 0.90 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7856722 | 0.89 | TNF (0.56) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7856030 | 0.88 | KMT2A (0.57) | — | |
| SCHEMBL8779410 | 0.85 | TNF (0.49) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3690301 | 0.85 | PDE4A (0.52) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8421923 | 0.83 | TNF (0.56) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8421376 | 0.83 | TNF (0.56) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017070291-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-3142663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015175956-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-2583098-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORPORATION (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2555769-A2 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | Celgene Corporation (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011159750-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORPORATION (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2395995-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | CELGENE CORPORATION (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011127019-A2 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | CELGENE CORPORATION (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2010093588-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | CELGENE CORPORATION (US) | 2010-08-19 | — | — | WO | disclosed |
| EP-1744748-A4 | METHOD OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF MYELODYSPLASTIC SYNDROMES | CELGENE CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2004037207-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORPORATION (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004034962-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING MYELODYSPLASTIC SYNDROME | CELGENE CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003097040-A1 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003086373-A1 | METHODS FOR IDENTIFICATION OF MODULATORS OF ANGIOGENESIS, COMPOUNDS DISCOVERED THEREBY, AND METHODS OF TREATMENT USING THE COMPOUNDS | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087333-A2 | MODULATION OF STEM AND PROGENITOR CELL DIFFERENTIATION, ASSAYS, AND USES THEREOF | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1242082-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORPORATION (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001043743-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORP. (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-1035848-A4 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1035848-A1 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999006041-A1 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS | CELGENE CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |